Comprehensive Physiology Wiley Online Library
For Librarians For Authors Editors About

The Kallikrein‐Kinin System as a Regulator of Cardiovascular and Renal Function

Nour‐Eddine Rhaleb, Xiao‐Ping Yang, Oscar A. Carretero

10.1002/cphy.c100053

Source: Volume 1, Issue 2, April 2011

Published online: April 2011

Full Article on Wiley Online Library



Abstract

Autocrine, paracrine, endocrine, and neuroendocrine hormonal systems help regulate cardio‐vascular and renal function. Any change in the balance among these systems may result in hypertension and target organ damage, whether the cause is genetic, environmental or a combination of the two. Endocrine and neuroendocrine vasopressor hormones such as the renin‐angiotensin system (RAS), aldosterone, and catecholamines are important for regulation of blood pressure and pathogenesis of hypertension and target organ damage. While the role of vasodepressor autacoids such as kinins is not as well defined, there is increasing evidence that they are not only critical to blood pressure and renal function but may also oppose remodeling of the cardiovascular system.

Here we will primarily be concerned with kinins, which are oligopeptides containing the aminoacid sequence of bradykinin. They are generated from precursors known as kininogens by enzymes such as tissue (glandular) and plasma kallikrein. Some of the effects of kinins are mediated via autacoids such as eicosanoids, nitric oxide (NO), endothelium‐derived hyperpolarizing factor (EDHF), and/or tissue plasminogen activator (tPA). Kinins help protect against cardiac ischemia and play an important part in preconditioning as well as the cardiovascular and renal protective effects of angiotensin‐converting enzyme (ACE) and angiotensin type 1 receptor blockers (ARB).

But the role of kinins in the pathogenesis of hypertension remains controversial. A study of Utah families revealed that a dominant kallikrein gene expressed as high urinary kallikrein excretion was associated with a decreased risk of essential hypertension. Moreover, researchers have identified a restriction fragment length polymorphism (RFLP) that distinguishes the kallikrein gene family found in one strain of spontaneously hypertensive rats (SHR) from a homologous gene in normotensive Brown Norway rats, and in recombinant inbred substrains derived from these SHR and Brown Norway rats this RFLP cosegregated with an increase in blood pressure. However, humans, rats and mice with a deficiency in one or more components of the kallikrein‐kinin‐system (KKS) or chronic KKS blockade do not have hypertension. In the kidney, kinins are essential for proper regulation of papillary blood flow and water and sodium excretion. B2‐KO mice appear to be more sensitive to the hypertensinogenic effect of salt. Kinins are involved in the acute antihypertensive effects of ACE inhibitors but not their chronic effects (save for mineralocorticoid‐salt‐induced hypertension).

Kinins appear to play a role in the pathogenesis of inflammatory diseases such as arthritis and skin inflammation; they act on innate immunity as mediators of inflammation by promoting maturation of dendritic cells, which activate the body's adaptive immune system and thereby stimulate mechanisms that promote inflammation. On the other hand, kinins acting via NO contribute to the vascular protective effect of ACE inhibitors during neointima formation. In myocardial infarction produced by ischemia/reperfusion, kinins help reduce infarct size following preconditioning or treatment with ACE inhibitors. In heart failure secondary to infarction, the therapeutic effects of ACE inhibitors are partially mediated by kinins via release of NO, while drugs that activate the angiotensin type 2 receptor act in part via kinins and NO. Thus kinins play an important role in regulation of cardiovascular and renal function as well as many of the beneficial effects of ACE inhibitors and ARBs on target organ damage in hypertension. © 2011 American Physiological Society. Compr Physiol 1:971‐993, 2011.

Comprehensive Physiology offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images


Figure 1. Figure 1.

Site of kininogen cleavage (solid arrows) by the main kininogenases (glandular and plasma kallikrein). The broken arrows indicate sites of kinin cleavage by kininases (kininase I, kininase II, neutral endopeptidases 24.11 and 24.15, and aminopeptidases). [Modified after Carretero and Scicli 49.]
Figure 2. Figure 2.

Kinins act via the B2 and B1 receptors. Most of the known effects of kinins are mediated by the B2 receptor that in terms act by stimulating the release of various intermediaries: eicosanoids, endothelial derive hyperpolarizing factor (EDRF), nitric oxide (NO), tissue plasminogen activator (tPA), glucose transporter (GLU‐1 and ‐2 [modified from 42].
Figure 3. Figure 3.

Kinins participate in the activation of the innate/adaptive immunity in a variety of acute and/or chronic inflammatory diseases. Upon tissue injury, kinins via activation of dendritic cells (DCs) B2 receptors triggered mechanism related to maturation of DCs, including migration to sites of inflammation and release of proinflammatory cytokines and chemokines such as IL‐12, which promote differentiation of naive CD4+ to Th1 and CD8+ cytotoxic effector T cells (CETCs) producing IFN‐γ and other proinflammatory cytokines, reaching infected or injured peripheral tissues such as lung, kidneys, heart or brain 244. [Modified from Monteiro et al. 175.] Copyright 2009. The American Association of Immunologists, Inc.
Figure 4. Figure 4.

Localization of the kallikrein‐kinin system along the nephron. Kallikrein is produced in the convoluted connecting tubule, kininogens in the cortical portion of the collecting duct and kinins along the collecting duct. Filtered blood kinins are mainly destroyed by kininases located along the proximal tubule. Activation of kinin receptors in the nephron leads to production of prostaglandin E2 (PGE2) along the medullary portion of the collecting duct. Drawing of the nephron was kindly provided by Dr. William H. Beierwaltes.
Figure 5. Figure 5.

Diurnal and nocturnal mean blood pressure of bradykinin B2 receptor knockout (−/−) and wild type (+/+) mice. Blood pressure was measured 24 h by a telemetric system (Rhaleb N‐E and Carretero O.A. unpublished data).
Figure 6. Figure 6.

ACE has multiple substrates, and inhibition of their hydrolysis may explain the cardioprotective effect of ACE inhibitors.
Figure 7. Figure 7.

Antihypertensive effect of ACE inhibitor in bradykinin B2 receptor knockout (−/−) mice. Mice with 2K‐1C hypertension were given plain water (vehicle) or water mixed with ACE inhibitor, ramipril, (4 mg/kg/day) to drink 5 weeks after blood pressure was increased. ACE inhibitor normalized blood pressure in B2−/− hypertensive mice. *P < 0.001, 2K‐1C versus sham; **P < 0.001, 2K‐1C versus 2K‐1C + ramipril. (Rhaleb N‐E and Carretero O.A. unpublished data.)
Figure 8. Figure 8.

Role of kinins in the acute antihypertensive effects an ACE inhibitor (enalaprilat) in rats with severe hypertension. Top: Blood kinin concentrations before (C) and after administration of the ACE inhibitor. Bottom: Mean blood pressure before and after ACE inhibition, open and closed circles represent rats pretreated with a kinin antagonist or vehicle, respectively. Values are mean ± SEM (bottom). [Reprinted from Carbonell et al. 40.]
Figure 9. Figure 9.

Two‐dimensional M‐mode echocardiographs of B2−/− mice and B2+/+ mice with sham coronary ligation (sham) or heart failure induced by coronary artery ligation. ACE inhibitor ramipril (2.5 mg/kg/day) reduced LV chamber size and thickeness in B2+/+, but only marginally in B2−/−, indicating an important role of kinin in the cardoprotective effects of ACE inibition in heart failure model. IS indicates interventricular septum; DD, left ventricular (LV) diastolic dimension; and PW, LV posterior wall. (Reprinted from Yang et al. 311.]
Figure 10. Figure 10.

Effect of prolylcarboxypeptidase (PRCP) blockade by a siRNA on bradykinin (BK) release in Ad‐AT2R‐transfected mouse coronary endothelial cells (ECs). (A) Representative Western blot showing PRCP protein expression (top) and quantitative analysis of PRCP protein (bottom); PRCP SiRNA, but not scarmbled‐SiRNA (S‐siRNA) significantly blocked PRCP expression. (B) Fold change in bradykinin release relative to Ad‐GFP‐transfected cells; BK release was further increased when Ad‐AT2R‐transfected ECs were treated with CGP42112A, a selective AT2 agonist (CGP; 0.1 μmol/l). SiRNA, but not S‐siRNA significantly blunted Ad‐AT2R‐induced bradykinin release. n = 4. [Reprinted from Zhu, Carretero, Yang et al., 318.]
Figure 11. Figure 11.

The renin‐angiotensin and kallikrein‐kinin systems. In both systems, a substrate is cleaved by an enzyme of restricted specificity, releasing a peptide that is either already active (lys‐bradykinin, bradykinin) or inactive (angiotensin I). Upon further processing by a specific peptidase, angiotensin I is converted to a vasoactive peptide (angiotensin II). In turn, vasoactive peptides are inactivated by peptidases. Angiotensin‐converting enzyme is common to both systems but has different roles: it processes angiotensin I to angiotensin II and is the main kinin‐inactivating peptidase. [Reprinted from Liu et al. 143.]


Figure 1.

Site of kininogen cleavage (solid arrows) by the main kininogenases (glandular and plasma kallikrein). The broken arrows indicate sites of kinin cleavage by kininases (kininase I, kininase II, neutral endopeptidases 24.11 and 24.15, and aminopeptidases). [Modified after Carretero and Scicli 49.]



Figure 2.

Kinins act via the B2 and B1 receptors. Most of the known effects of kinins are mediated by the B2 receptor that in terms act by stimulating the release of various intermediaries: eicosanoids, endothelial derive hyperpolarizing factor (EDRF), nitric oxide (NO), tissue plasminogen activator (tPA), glucose transporter (GLU‐1 and ‐2 [modified from 42].



Figure 3.

Kinins participate in the activation of the innate/adaptive immunity in a variety of acute and/or chronic inflammatory diseases. Upon tissue injury, kinins via activation of dendritic cells (DCs) B2 receptors triggered mechanism related to maturation of DCs, including migration to sites of inflammation and release of proinflammatory cytokines and chemokines such as IL‐12, which promote differentiation of naive CD4+ to Th1 and CD8+ cytotoxic effector T cells (CETCs) producing IFN‐γ and other proinflammatory cytokines, reaching infected or injured peripheral tissues such as lung, kidneys, heart or brain 244. [Modified from Monteiro et al. 175.] Copyright 2009. The American Association of Immunologists, Inc.



Figure 4.

Localization of the kallikrein‐kinin system along the nephron. Kallikrein is produced in the convoluted connecting tubule, kininogens in the cortical portion of the collecting duct and kinins along the collecting duct. Filtered blood kinins are mainly destroyed by kininases located along the proximal tubule. Activation of kinin receptors in the nephron leads to production of prostaglandin E2 (PGE2) along the medullary portion of the collecting duct. Drawing of the nephron was kindly provided by Dr. William H. Beierwaltes.



Figure 5.

Diurnal and nocturnal mean blood pressure of bradykinin B2 receptor knockout (−/−) and wild type (+/+) mice. Blood pressure was measured 24 h by a telemetric system (Rhaleb N‐E and Carretero O.A. unpublished data).



Figure 6.

ACE has multiple substrates, and inhibition of their hydrolysis may explain the cardioprotective effect of ACE inhibitors.



Figure 7.

Antihypertensive effect of ACE inhibitor in bradykinin B2 receptor knockout (−/−) mice. Mice with 2K‐1C hypertension were given plain water (vehicle) or water mixed with ACE inhibitor, ramipril, (4 mg/kg/day) to drink 5 weeks after blood pressure was increased. ACE inhibitor normalized blood pressure in B2−/− hypertensive mice. *P < 0.001, 2K‐1C versus sham; **P < 0.001, 2K‐1C versus 2K‐1C + ramipril. (Rhaleb N‐E and Carretero O.A. unpublished data.)



Figure 8.

Role of kinins in the acute antihypertensive effects an ACE inhibitor (enalaprilat) in rats with severe hypertension. Top: Blood kinin concentrations before (C) and after administration of the ACE inhibitor. Bottom: Mean blood pressure before and after ACE inhibition, open and closed circles represent rats pretreated with a kinin antagonist or vehicle, respectively. Values are mean ± SEM (bottom). [Reprinted from Carbonell et al. 40.]



Figure 9.

Two‐dimensional M‐mode echocardiographs of B2−/− mice and B2+/+ mice with sham coronary ligation (sham) or heart failure induced by coronary artery ligation. ACE inhibitor ramipril (2.5 mg/kg/day) reduced LV chamber size and thickeness in B2+/+, but only marginally in B2−/−, indicating an important role of kinin in the cardoprotective effects of ACE inibition in heart failure model. IS indicates interventricular septum; DD, left ventricular (LV) diastolic dimension; and PW, LV posterior wall. (Reprinted from Yang et al. 311.]



Figure 10.

Effect of prolylcarboxypeptidase (PRCP) blockade by a siRNA on bradykinin (BK) release in Ad‐AT2R‐transfected mouse coronary endothelial cells (ECs). (A) Representative Western blot showing PRCP protein expression (top) and quantitative analysis of PRCP protein (bottom); PRCP SiRNA, but not scarmbled‐SiRNA (S‐siRNA) significantly blocked PRCP expression. (B) Fold change in bradykinin release relative to Ad‐GFP‐transfected cells; BK release was further increased when Ad‐AT2R‐transfected ECs were treated with CGP42112A, a selective AT2 agonist (CGP; 0.1 μmol/l). SiRNA, but not S‐siRNA significantly blunted Ad‐AT2R‐induced bradykinin release. n = 4. [Reprinted from Zhu, Carretero, Yang et al., 318.]



Figure 11.

The renin‐angiotensin and kallikrein‐kinin systems. In both systems, a substrate is cleaved by an enzyme of restricted specificity, releasing a peptide that is either already active (lys‐bradykinin, bradykinin) or inactive (angiotensin I). Upon further processing by a specific peptidase, angiotensin I is converted to a vasoactive peptide (angiotensin II). In turn, vasoactive peptides are inactivated by peptidases. Angiotensin‐converting enzyme is common to both systems but has different roles: it processes angiotensin I to angiotensin II and is the main kinin‐inactivating peptidase. [Reprinted from Liu et al. 143.]

References
 1. The Kinin System (The Handbook of Immunopharmacology). In: Farmer SG, editor. San Diego, CA: Academic Press Inc, pp. 1–323, 1997.
 2. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2‐receptor‐null mice. Hypertension 42: 600–604, 2003.
 3. Abadir PM, Periasamy A, Carey RM, Siragy HM. Angiotensin II type 2 receptor‐bradykinin B2 receptor functional heterodimerization. Hypertension 48: 1–7, 2006.
 4. Abbas A, Gorelik G, Carbini LA, Scicli AG. Angiotensin‐(1‐7) induces bradykinin‐mediated hypotensive responses in anesthetized rats. Hypertension 30: 217–221, 1997.
 5. AbdAlla S, Abdel‐Baset A, Lother H, el Massiery A, Quitterer U. Mesangial AT1/B2 receptor heterodimers contribute to angiotensin II hyperresponsiveness in experimental hypertension. J Mol Neurosci 26: 185–192, 2005.
 6. AbdAlla S, Lother H, el Massiery A, Quitterer U. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med 7: 1003–1009, 2001.
 7. AbdAlla S, Lother H, Quitterer U. AT1‐receptor heterodimers show enhanced G‐protein activation and altered receptor sequestration. Nature 407: 94–98, 2000.
 8. AbdAlla S, Zaki E, Lother H, Quitterer U. Involvement of the amino terminus of the B(2) receptor in agonist‐induced receptor dimerization. J Biol Chem 274: 26079–26084, 1999.
 9. Agarwal D, Haque M, Sriramula S, Mariappan N, Pariaut R, Francis J. Role of proinflammatory cytokines and redox homeostasis in exercise‐induced delayed progression of hypertension in spontaneously hypertensive rats. Hypertension 54: 1393–1400, 2009.
 10. Alfie ME, Yang X‐P, Hess F, Carretero OA. Salt‐sensitive hypertension in bradykinin B2 receptor knockout mice. Biochem Biophys Res Commun 224: 625–630, 1996.
 11. Alhenc‐Gelas F, Marchetti J, Allegrini J, Corvol P, Menard J. Measurement of urinary kallikrein activity. Species differences in kinin production. Biochim Biophys Acta 677: 477–488, 1981.
 12. Aliberti J, Viola JP, Vieira‐de‐Abreu A, Bozza PT, Sher A, Scharfstein J. Cutting edge: Bradykinin induces IL‐12 production by dendritic cells: a danger signal that drives Th1 polarization. J Immunol 170: 5349–5353, 2003.
 13. Azizi M, Boutouyrie P, Bissery A, Aghrarazii M, Verbeke F, Stern N, Bura‐Rivière A, Laurent S, Alhenc‐Gelas F, Jeunemaitre X. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest 115: 780–787, 2005.
 14. Bao G, Gohlke P, Qadri F, Unger T. Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. Hypertension 20: 74–79, 1992.
 15. Barki‐Harrington L, Bookout AL, Wang G, Lamb ME, Leeb‐Lundberg LM, Daaka Y. Requirement for direct cross‐talk between B1 and B2 kinin receptors for the proliferation of androgen‐insensitive prostate cancer PC3 cells. Biochem J 371: 581–587, 2003.
 16. Barlas A, Okamoto H, Greenbaum LM. T‐kininogen – the major plasma kininogen in rat adjuvant arthritis. Biochem Biophys Res Commun 129: 280–286, 1985.
 17. Bascands JL, Bachvarova M, Neau E, Schanstra JP, Bachvarov D. Molecular determinants of LPS‐induced acute renal inflammation: Implication of the kinin B1 receptor. Biochem Biophys Res Commun 386: 407–412, 2009.
 18. Baumgarten G, Knuefermann P, Kalra D, Gao F, Taffet GE, Michael L, Blackshear PJ, Carballo E, Sivasubramanian N, Mann DL. Load‐dependent and ‐independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. Circulation 105: 2192–2197, 2002.
 19. Beierwaltes WH, Carretero OA, Scicli AG. Renal hemodynamics in response to a kinin analogue antagonist. Am J Physiol 255: F408–F414, 1988.
 20. Beierwaltes WH, Carretero OA, Scicli AG, Vavrek RJ, Stewart JM. Competitive analog antagonists of bradykinin in the canine hindlimb. Proc Soc Exp Biol Med 186: 79–83, 1987.
 21. Benetos A, Gavras H, Stewart JM, Vavrek RJ, Hatinoglou S, Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension 8: 971–974, 1986.
 22. Benetos A, Gavras I, Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension 8: 1089–1092, 1986.
 23. Berg T, Carretero OA, Scicli AG, Tilley B, Stewart JM. Role of kinin in regulation of rat submandibular gland blood flow. Hypertension 14: 73–80, 1989.
 24. Bergaya S, Hilgers RH, Meneton P, Dong Y, Bloch‐Faure M, Inagami T, Alhenc‐Gelas F, Lévy BI, Boulanger CM. Flow‐dependent dilation mediated by endogenous kinins requires angiotensin AT2 receptors. Circ Res 94: 1623–1629, 2004.
 25. Bergaya S, Meneton P, Bloch‐Faure M, Mathieu E, henc‐Gelas F, Levy BI, Boulanger CM. Decreased flow‐dependent dilation in carotid arteries of tissue kallikrein‐knockout mice. Circ Res 88: 593–599, 2001.
 26. Blanchard A, Azizi M, Peyrard S, Stern N, henc‐Gelas F, Houillier P, Jeunemaitre X. Partial human genetic deficiency in tissue kallikrein activity and renal calcium handling. Clin J Am Soc Nephrol 2: 320–325, 2007.
 27. Bock MG, Longmore J. Bradykinin antagonists: new opportunities. Curr Opin Chem Biol 4: 401–406, 2000.
 28. Bönner G, Preis S, Schunk U, Toussaint C, Kaufmann W. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 15 (Suppl 6): S46–S56, 1990.
 29. Boucher R, Demassieux S, Garcia R, Genest J. Tonin, angiotensin II system. Circ Res 41: 26–29, 1977.
 30. Brew EC, Mitchell MB, Rehring TF, Gamboni‐Robertson F, McIntyre RC Jr, Harken AH, Banerjee A. Role of bradykinin in cardiac functional protection after global ischemia‐reperfusion in rat heart. Am J Physiol 269: H1370–H1378, 1995.
 31. Brosnihan KB, Li P, Ferrario CM. Angiotensin‐(1‐7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523–528, 1996.
 32. Bueno OF, Molkentin JD. Involvement of extracellular signal‐regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776–781, 2002.
 33. Burch RM, Farmer SG, Steranka LR. Bradykinin receptor antagonists. Med Res Rev 10: 237–269, 1990.
 34. Burgess GM, Perkins MN, Rang HP, Campbell EA, Brown MC, Mcintyre P, Urban L, Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Wrigglesworth R, Lee W, Davis C, Phagoo SB, Davis AJ, Phillips E, Drake GS, Hughes GA, Dunstan A, Bloomfield GC. Bradyzide, a potent non‐peptide B(2) bradykinin receptor antagonist with long‐lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 129: 77–86, 2000.
 35. Cachofeiro V, Sakakibara T, Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension 19: 138–145, 1992.
 36. Campbell DJ. The kallikrein‐kinin system in humans. Clin Exp Pharmacol Physiol 28: 1060–1065, 2001.
 37. Campbell DJ, Kladis A, Duncan A‐M. Bradykinin peptides in kidney, blood, and other tissues of the rat. Hypertension 21: 155–165, 1993.
 38. Carbini LA, Scicli AG, Carretero OA. The molecular biology of the kallikrein‐kinin system: III. The human kallikrein gene family and kallikrein substrate. J Hypertens 11: 893–898, 1993.
 39. Carbonell LF, Carretero OA, Madeddu P, Scicli AG. Effects of a kinin antagonist on mean blood pressure. Hypertension 11 (Suppl I): I–84‐I‐88, 1988.
 40. Carbonell LF, Carretero OA, Stewart JM, Scicli AG. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension 11: 239–243, 1988.
 41. Carretero OA. High‐mineralocorticoid conditions: Kinins (paracrine hormones) in the regulation of renal function and blood pressure. In: Mornex R, Jaffiol C, Leclère J, editors. Progress in Endocrinology. The Proceedings of the Ninth International Congress of Endocrinology, Nice 1992. Carnforth, Lancastershire, UK: Parthenon Publications Group, 1993a, p. 536–540.
 42. Carretero OA. Kinins: local hormones in regulation of blood pressure and renal function. Choices Cardiol 7 (Suppl 1): 10–14, 1993b.
 43. Carretero OA, Amin VM, Ocholik T, Scicli AG, Koch J. Urinary kallikrein in rats bred for their susceptibility and resistance to the hypertensive effect of salt. A new radioimmunoassay for its direct determination. Circ Res 42: 727–731, 1978.
 44. Carretero OA, Carbini LA, Scicli AG. The molecular biology of the kallikrein‐kinin system: I. General description, nomenclature and the mouse gene family. J Hypertens 11: 693–697, 1993.
 45. Carretero OA, Kuk P, Piwonska Ss, Houle JA, Marin‐Grez M. Role of the renin‐angiotensin system in the pathogenesis of severe hypertension in rats. Circ Res 29: 654–663, 1971.
 46. Carretero OA, Miyazaki S, Scicli AG. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension 3: 18–22, 1981.
 47. Carretero OA, Polomski C, Hampton A, Scicli AG. Urinary kallikrein, plasma renin and aldosterone in New Zealand genetically hypertensive (GH) rats. Clin Exp Pharmacol Physiol 3 (Suppl): 55–59, 1976.
 48. Carretero OA, Scicli AG. The renal kallikrein‐kinin system in human and in experimental hypertension. Klin Wochenschr 56[Suppl. I]: 113–125, 1978.
 49. Carretero OA, Scicli AG. Kinins paracrine hormone. Kidney Int 34 (Suppl 26): S–52‐S‐59, 1988.
 50. Carretero OA, Scicli AG. The kallikrein‐kinin system as a regulator of cardiovascular and renal function. In: Laragh JH, Brenner BM, editors. Hypertension: Physiology, Diagnosis, and Management. New York: Raven Press, 1995, p. 983–999.
 51. Carretero OA, Scicli AG, Maitra SR. Role of kinins in the pharmacological effects of converting enzyme inhibitors. In: Horovitz ZP, editor. Angiotensin Converting Enzyme Inhibitors. Mechanisms of Action and Clinical Implications. Baltimore: Urban & Schwarzenberg, 1981, p. 105–121.
 52. Carretero OA, Scicli AG, Piwonska A, Koch J. Urinary kallikrein in rats bred for susceptibility and resistance to the hypertensive effect of salt and in New Zealand genetically hypertensive rats. Mayo Clin Proc 52: 465–467, 1977.
 53. Carretero OA, Ørstavik TB, Rabito SF, Scicli AG. Interference of converting enzyme inhibitors with the kallikrein‐kinin system. Clin Exp Hypertens A 5: 1277–1285, 1983.
 54. Cassim B, Shaw OM, Mazur M, Misso NL, Naran A, Langlands DR, Thompson PJ, Bhoola KD. Kallikreins, kininogens and kinin receptors on circulating and synovial fluid neutrophils: role in kinin generation in rheumatoid arthritis. Rheumatology (Oxford) 48: 490–496, 2009.
 55. Cervenka L, Harrison‐Bernard LM, Dipp S, Primrose G, Imig JD, El‐Dahr SS. Early onset salt‐sensitive hypertension in bradykinin B2 receptor null mice. Hypertension 34: 176–180, 1999.
 56. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS. C‐reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 104: 145–150, 2001.
 57. Chao J, Chao L, Margolius HS. Isolation of tissue kallikrein in rat spleen by monoclonal antibody‐affinity chromatography. Biochim Biophys Acta 801: 244–249, 1984.
 58. Chao J, Chao L, Swain CC, Tsai J, Margolius HS. Tissue kallikrein in rat brain and pituitary: regional distribution and estrogen induction in the anterior pituitary. Endocrinology 120: 475–482, 1987.
 59. Chao J, Li HJ, Yao YY, Shen B, Gao L, Bledsoe G, Chao L. Kinin infusion prevents renal inflammation, apoptosis, and fibrosis via inhibition of oxidative stress and mitogen‐activated protein kinase activity. Hypertension 49: 490–497, 2007.
 60. Chappell MC, Allred AJ, Ferrario CM. Pathways of angiotensin‐(1‐7) metabolism in the kidney. Nephrol Dial Transplant 16 (Suppl 1): 22–26, 2001.
 61. Chappell MC, Gomez MN, Pirro NT, Ferrario CM. Release of angiotensin‐(1‐7) from the rat hindlimb. Influence of angiotensin‐converting enzyme inhibition. Hypertension 35: 348–352, 2000.
 62. Cherry PD, Furchgott RF, Zawadzki JV, Jothianandan D. Role of endothelial cells in relaxation of isolated arteries by bradykinin. Proc Natl Acad Sci USA 79: 2106–2110, 1982.
 63. Cialdai C, Giuliani S, Valenti C, Tramontana M, Maggi CA. Effect of intra‐articular 4‐(S)‐amino‐5‐(4‐{4‐[2,4‐dichloro‐3‐(2,4‐dimethyl‐8‐quinolyloxymethyl)phenylsulfo namido]‐tetrahydro‐2H‐4‐pyranylcarbonyl} piperazino)‐5‐oxopentyl](trimethyl)ammonium chloride hydrochloride (MEN16132), a kinin B2 receptor antagonist, on nociceptive response in monosodium iodoacetate‐induced experimental osteoarthritis in rats. J Pharmacol Exp Ther 331: 1025–1032, 2009.
 64. Clappison BH, Anderson WP, Johnston CI. Role of the kallikrein‐kinin system in the renal effects of angiotensin‐converting enzyme inhibition in anaesthetized dogs. Clin Exp Pharmacol Physiol 8: 509–513, 1981.
 65. Clements JA. The glandular kallikrein family of enzymes: Tissue‐specific expression and hormonal regulation. Endocr Rev 10: 393–419, 1989.
 66. Clements JA, Matheson BA, MacDonald RJ, Funder JW. The expression of the kallikrein gene family in the rat pituitary: oestrogen effects and the expression of an additional family member in the neurointermediate lobe. J Neuroendocrinol 1: 199–203, 1989.
 67. Clozel M. Mechanism of action of angiotensin converting enzyme inhibitors on endothelial function in hypertension. Hypertension 18 (Suppl II): II–37‐II‐42, 1991.
 68. Cohuet G, Struijker‐Boudier H. Mechanisms of target organ damage caused by hypertension: Therapeutic potential. Pharmacol Ther 111: 81–98, 2006.
 69. Colman RW. Patho‐physiology of kallikrein system. Ann Clin Lab Sci 10: 220–226, 1980.
 70. Danckwardt L, Shimizu I, Bönner G, Rettig R, Unger T. Converting enzyme inhibition in kinin‐deficient Brown Norway rats. Hypertension 16: 429–435, 1990.
 71. Dear JW, Foreman JC. The nasal airway pharmacology of bradykinin. In: Farmer SG, editor. The Kinin System. San Diego, CA: Academic Press Inc, 1997, p. 287–300.
 72. Duka A, Kintsurashvili E, Duka I, Ona D, Hopkins TA, Bader M, Gavras I, Gavras H. Angiotensin‐converting enzyme inhibition after experimental myocardial infarct: role of the kinin B1 and B2 receptors. Hypertension 51: 1352–1357, 2008.
 73. Emanueli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, Salis MB, Straino S, Capogrossi MC, Olivetti G, Madeddu P. Dilated and failing cardiomyopathy in bradykinin B2 receptor knockout mice. Circulation 100: 2359–2365, 1999.
 74. Erdös EG. Angiotensin I converting enzyme. Circ Res 36: 247–255, 1975.
 75. Erdös EG. Kininases. In: Erdös EG, editor. Handbook of Experimental Pharmacology, Vol. XXV Suppl: Bradykinin, Kallidin and Kallikrein. Berlin: Springer‐Verlag, 1979, p. 427–487.
 76. Farhy R, Ho K‐L, Carretero OA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 182: 283–288, 1992.
 77. Farhy RD, Carretero OA, Ho K‐L, Scicli AG. Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ Res 72: 1202–1210, 1993.
 78. Farmer SG. The kallikrein‐kinin system in asthma and acute respiratory distress syndrome. In: Farmer SG, editor. The Kinin System. San Diego, CA: Academic Press Inc, 1997, p. 249–263.
 79. Fernandez LA, Twickler J, Mead A. Neovascularization produced by angiotensin II. J Lab Clin Med 105: 141–145, 1985.
 80. Ferrario CM. Angiotensin‐(1‐7) and antihypertensive mechanisms. J Nephrol 11: 278–283, 1998.
 81. Ferrario CM, Averill DB, Brosnihan KB, Chappell MC, Iskandar SS, Dean RH, Diz DI. Vasopeptidase inhibition and Ang‐(1‐7) in the spontaneously hypertensive rat. Kidney Int 62: 1349–1357, 2002.
 82. Figueroa CD, MacIver AG, Mackenzie JC, Bhoola KD. Localisation of immunoreactive kininogen and tissue kallikrein in the human nephron. Histochemistry 89: 437–442, 1988.
 83. Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. Angiotensin‐(1‐7) inhibits vascular smooth muscle cell growth. Hypertension 28: 104–108, 1996.
 84. Frey EK, Kraut H, Werle E. Kallikrein Padutin [English transl. (1977) edited by R. Vogel). Stuttgart: Ferdinand Enke Verlag, 1950.
 85. Furuichi K, Gao JL, Horuk R, Wada T, Kaneko S, Murphy PM. Chemokine receptor CCR1 regulates inflammatory cell infiltration after renal ischemia‐reperfusion injury. J Immunol 181: 8670–8676, 2008.
 86. Furuto‐Kato S, Matsumoto A, Kitamura N, Nakanishi S. Primary structures of the mRNAs encoding the rat precursors for bradykinin and T‐kinin. Structural relationship of kininogens with major acute phase protein and α1‐cysteine proteinase inhibitor. J Biol Chem 260: 12054–12059, 1985.
 87. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin‐receptor blockade on the response to angiotensin‐converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 339: 1285–1292, 1998.
 88. Geiger R, Clausnitzer B, Fink E, Fritz H. Isolation of an enzymatically active glandular kallikrein from human plasma by immunoaffinity chromatography. Hoppe Seylers Z Physiol Chem 361: 1795–1803, 1980.
 89. Gertz SD, Kurgan A. Tissue plasminogen activator and selective coronary vasodilation [letter]. Am J Cardiol 62: 173, 1988.
 90. Gohlke P, Kuwer I, Schnell A, Amann K, Mall G, Unger T. Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin‐converting enzyme inhibitor treatment in stroke‐prone spontaneously hypertensive rats. Hypertension 29: 478–482, 1997.
 91. Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. Angiotensin‐converting enzyme inhibition improves cardiac function. Role of bradykinin. Hypertension 23: 411–418, 1994.
 92. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin‐dependent mechanism. Hypertension 31: 349–355, 1998.
 93. Gorelik G, Carbini LA, Scicli AG. Angiotensin 1‐7 induces bradykinin‐mediated relaxation in porcine coronary artery. J Pharmacol Exp Ther 286: 403–410, 1998.
 94. Goto M, Liu Y, Yang X‐M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 77: 611–621, 1995.
 95. Griol‐Charhbili V, Messadi‐Laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, henc‐Gelas F, Richer C. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J 19: 1172–1174, 2005.
 96. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II‐induced hypertension and vascular dysfunction. J Exp Med 204: 2449–2460, 2007.
 97. Hall JM, Morton IKM. The pharmacology and immunopharmacology of kinin receptors. In: Farmer SG, editor. The Kinin System. San Diego, CA: Academic Press Inc, 1997, p. 9–43.
 98. Hansen JL, Hansen JT, Speerschneider T, Lyngso C, Erikstrup N, Burstein ES, Weiner DM, Walther T, Makita N, Iiri T, Merten N, Kostenis E, Sheikh SP. Lack of evidence for AT1R/B2R heterodimerization in COS‐7, HEK293, and NIH3T3 cells: How common is the AT1R/B2R heterodimer? J Biol Chem 284: 1831–1839, 2009.
 99. Hara DB, Leite DF, Fernandes ES, Passos GF, Guimaraes AO, Pesquero JB, Campos MM, Calixto JB. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br J Pharmacol 154: 1276–1286, 2008.
 100. Harrison DG, Guzik TJ, Goronzy J, Weyand C. Is hypertension an immunogic disease? Curr Cardiol Rep 10: 464–469, 2009.
 101. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 21: 996–1003, 1993.
 102. Hashimoto K, Hamamoto H, Honda Y, Hirose M, Furukawa S, Kimura E. Changes in components of kinin system and hemodynamics in acute myocardial infarction. Am Heart J 95: 619–626, 1978.
 103. Hecquet C, Tan F, Marcic BM, Erdös EG. Human bradykinin B2 receptor is activated by kallikrein and other serine proteases. Mol Pharmacol 58: 828–836, 2000.
 104. Heitsch H. Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect 13: 213–225, 2000.
 105. Heitsch H. The therapeutic potential of bradykinin B2 receptor agonists in the treatment of cardiovascular disease. Expert Opin Investig Drugs 12: 759–770, 2003.
 106. Hilton SM. The physiological role of glandular kallikreins. In: Erdös EG, editor. Handbook of Experimental Pharmacology, Vol. 25: Bradykinin, Kallidin and Kallikrein. New York: Springer‐Verlag, 1970, p. 389–399.
 107. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, Weyand C, Harrison DG. Regulation of T‐cell function by endogenously produced angiotensin II. Am J Physiol Regul Integr Comp Physiol 296: R208–R216, 2009.
 108. Holland OB, Chud JM, Braunstein H. Urinary kallikrein excretion in essential and mineralocorticoid hypertension. J Clin Invest 65: 347–356, 1980.
 109. Holton FA, Holton P. The vasodilator activity of spinal roots. J Physiol 118: 310–327, 1952.
 110. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdös EG. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I‐converting enzyme inhibitors and peptide ligands. Mol Pharmacol 66: 1310–1316, 2004.
 111. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG. Activation of bradykinin B1 receptor by ACE inhibitors. Int Immunopharmacol 2: 1787–1793, 2002.
 112. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG. Novel mode of action of angiotensin I converting enzyme inhibitors. Direct activation of bradykinin B1 receptor. J Biol Chem 277: 16847–16852, 2002.
 113. Ishida H, Scicli AG, Carretero OA. Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension 14: 322–327, 1989.
 114. Jacobsen S. Separation of two different substrates for plasma kinin‐forming enzymes. Nature 210: 98–99, 1966.
 115. Jacobsen S. Substrates for plasma kinin‐forming enzymes in human, dog and rabbit plasmas. Br J Pharmacol 26: 403–411, 1966.
 116. Ju H, Venema VJ, Marrero MB, Venema RC. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric‐oxide synthase. J Biol Chem 273: 24025–24029, 1998.
 117. Kakoki M, Sullivan KA, Backus C, Hayes JM, Oh SS, Hua K, Gasim AM, Tomita H, Grant R, Nossov SB, Kim HS, Jennette JC, Feldman EL, Smithies O. Lack of both bradykinin B1 and B2 receptors enhances nephropathy, neuropathy, and bone mineral loss in Akita diabetic mice. Proc Natl Acad Sci U S A 107: 10190–10195, 2010.
 118. Kaman WE, Wolterink AF, Bader M, Boele LC, Van Der KD. The bradykinin B2 receptor in the early immune response against Listeria infection. Med Microbiol Immunol 198: 39–46, 2009.
 119. Kaplan AP, Silverberg M. The coagulation‐kinin pathway of human plasma. Blood 70: 1–15, 1987.
 120. Kaplan AP, Silverberg M, Ghebrehiwet B, Atkins P, Zweiman B. The kallikrein‐kinin system in inflammation. Adv Exp Med Biol 247: 125–136, 1989.
 121. Kauker ML. Bradykinin action on the efflux of luminal 22Na in the rat nephron. J Pharmacol Exp Ther 214: 119–123, 1980.
 122. Kauker ML. Kallidin effect on renal tubular function in meclofenamate‐ and vehicle‐pretreated rats. Proc Soc Exp Biol Med 193: 60–64, 1990.
 123. Kauker ML, Gisi PJ, Zawada ET. Renal kinins and sodium transport: Influence of a bradykinin receptor antagonist (BKRA). FASEB J 4: A990, 1990.
 124. Keiser HR, Geller RG, Margolius HS, Pisano JJ. Urinary kallikrein in hypertensive animal models. Fed Proc 35: 199–202, 1976.
 125. Kellett DN. On the anti‐inflammatory activity of protamine sulphate and of hexadimethrine bromide, inhibitors of plasma kinin formation. Br J Pharmacol Chemother 24: 705–713, 1965.
 126. Kumamoto K, Stewart TA, Johnson AR, Erdos EG. Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest 67: 210–215, 1981.
 127. Kurisu S, Ozono R, Oshima T, Kambe M, Ishida T, Sugino H, Matsuura H, Chayama K, Teranishi Y, Iba O, Amano K, Matsubara H. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 41: 99–107, 2003.
 128. Lahera V, Salom MG, Fiksen‐Olsen MJ, Romero JC. Mediatory role of endothelium‐derived nitric oxide in renal vasodilatory and excretory effects of bradykinin. Am J Hypertens 4: 260–262, 1991.
 129. Lako‐Futo Z, Szokodi I, Sarman B, Foldes G, Tokola H, Ilves M, Leskinen H, Vuolteenaho O, Skoumal R, deChatel R, Ruskoaho H, Toth M. Evidence for a functional role of angiotensin II type 2 receptor in the cardiac hypertrophic process in vivo in the rat heart. Circulation 108: 2414–2422, 2003.
 130. Langberg H, Bjørn C, Boushel R, Hellsten Y, Kjær M. Exercise‐induced increase in interstitial bradykinin and adenosine concentrations in skeletal muscle and peritendinous tissue in humans. J Physiol 542: 977–983, 2002.
 131. Lawton WJ, Proud D, Frech ME, Pierce JV, Keiser HR, Pisano JJ. Characterization and origin of immunoreactive glandular kallikrein in rat plasma. Biochem Pharmacol 30: 1731–1737, 1981.
 132. Lewis GP. Plasma kinins and inflammation. Metabolism 13: 1256–1263, 1964.
 133. Liao T‐D, Yang X‐P, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA. Role of inflammation in the development of renal damage and dysfunction in angiotensin‐II‐induced hypertension. Hypertension 52: 256–263, 2008.
 134. Lilja H. A kallikrein‐like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76: 1899–1903, 1985.
 135. Linz W, Martorana PA, Schölkens BA. Local inhibition of bradykinin degradation in ischemic hearts. J Cardiovasc Pharmacol 15 (Suppl. 6): S99–S109, 1990.
 136. Linz W, Schölkens BA. A specific B2‐bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 105: 771–772, 1992.
 137. Linz W, Wiemer G, Schölkens BA. ACE‐inhibition induces NO‐formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J Mol Cell Cardiol 24: 909–919, 1992.
 138. Linz W, Wiemer G, Schölkens BA. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies. Diabetes 45 (Suppl. 1): S51–S58, 1996.
 139. Liu B, Linley JE, Du X, Zhang X, Ooi L, Zhang H, Gamper N. The acute nociceptive signals induced by bradykinin in rat sensory neurons are mediated by inhibition of M‐type K+ channels and activation of Ca2+‐activated Cl‐ channels. J Clin Invest 120: 1240–1252, 2010.
 140. Liu X, Lukasova M, Zubakova R, Lewicka S, Hilgenfeldt U. Kallidin‐like peptide mediates the cardioprotective effect of the ACE inhibitor captopril against ischaemic reperfusion injury of rat heart. Br J Pharmacol 148: 825–832, 2006.
 141. Liu YH, Xu J, Yang X‐P, Yang F, Shesely EG, Carretero OA. Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure. Hypertension 39: 375–381, 2002.
 142. Liu YH, Yang X‐P, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kininogen‐deficient rats. Am J Physiol Heart Circ Physiol 278: H507–H514, 2000.
 143. Liu YH, Yang X‐P, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin‐converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99: 1926–1935, 1997.
 144. Liu YH, Yang X‐P, Sharov VG, Sigmon DH, Sabbah HN, Carretero OA. Paracrine systems in the cardioprotective effect of angiotensin‐converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 27: 7–13, 1996.
 145. Liu YH, Yang X‐P, Shesely EG, Sankey SS, Carretero OA. Role of angiotensin II type 2 receptors and kinins in the cardioprotective effect of angiotensin II type 1 receptor antagonists in rats with heart failure. J Am Coll Cardiol 43: 1473–1480, 2004.
 146. Loke KE, Curran CML, Messina EJ, Laycock SK, Shesely EG, Carretero OA, Hintze TH. Role of nitric oxide in the control of cardiac oxygen consumption in B2‐kinin receptor knockout mice. Hypertension 34: 563–567, 1999.
 147. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Glorioso N. Chronic inhibition of bradykinin B2‐receptors enhances the slow vasopressor response to angiotensin II. Hypertension 23: 646–652, 1994.
 148. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Tonolo G, Troffa C, Glorioso N. Bradykinin B2‐receptor blockade facilitates deoxycorticosterone‐salt hypertension. Hypertension 21: 980–984, 1993.
 149. Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. Interleukin 17 Promotes Angiotensin II‐Induced Hypertension and Vascular Dysfunction. Hypertension 55: 500–507, 2009.
 150. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh‐Ishi S. Suppression of rat deoxycorticosterone‐salt hypertension by kallikrein‐kinin system. Hypertension 17: 806–813, 1991.
 151. Majima M, Mizogami S, Kuribayashi Y, Katori M, Oh‐Ishi S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen‐deficient rats. Hypertension 24: 111–119, 1994.
 152. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katori M, Oh‐Ishi S. High sensitivity to salt in kininogen‐deficient Brown Norway Katholiek rats. Hypertension 22: 705–714, 1993.
 153. Manolis AJ, Marketou ME, Gavras I, Gavras H. Cardioprotective properties of bradykinin: role of the B(2) receptor. Hypertens Res 33: 772–777, 2010.
 154. Marceau F. Kinin B1 receptor induction and inflammation. In: Farmer SG, editor. The Kinin System. San Diego, CA: Academic Press Inc, 1997, p. 143–156.
 155. Marceau F, Hess JF, Bachvarov DR. The B1 receptors for kinins. Pharmacol Rev 50: 357–386, 1998.
 156. Marceau F, Regoli D. Therapeutic options in inflammatory bowel disease: Experimental evidence of a beneficial effect of kinin B1 receptor blockade. Br J Pharmacol 154: 1163–1165, 2008.
 157. Marchesi C, Ebrahimian T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. Hypertension 54: 1384–1392, 2009.
 158. Marcic BM, Erdös EG. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I‐converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin. J Pharmacol Exp Ther 294: 605–612, 2000.
 159. Margolius HS, Horwitz D, Pisano JJ, Keiser HR. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium‐retaining steroids. Circ Res 35: 820–825, 1974.
 160. Marin Grez M. The influence of antibodies against bradykinin on isotonic saline diuresis in the rat. Evidence for kinin involvement in renal function. Pflugers Arch 350: 231–239, 1974.
 161. Marin‐Castaño ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader J‐L, Girolami J‐P, Bascands J‐L. Induction of functional bradykinin B1‐receptors in normotensive rats and mice under chronic angiotensin‐converting enzyme inhibitor treatment. Circulation 105: 627–632, 2002.
 162. Marks ES, Bing RF, Thurston H, Swales JD. Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin‐angiotensin blockade in the rat. Clin Sci 58: 1–6, 1980.
 163. Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. Reduction of infarct size by local angiotensin‐converting enzyme inhibition is abolished by a bradykinin antagonist. Eur J Pharmacol 182: 395–396, 1990.
 164. McCaa RE. Studies in vivo with angiotensin I converting enzyme (kininase II) inhibitors. Fed Proc 38: 2783–2787, 1979.
 165. McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. Expression cloning of a rat B2 bradykinin receptor. Proc Natl Acad Sci USA 88: 7724–7728, 1991.
 166. Meini S, Maggi CA. Knee osteoarthritis: A role for bradykinin? Inflamm Res 57: 351–361, 2008.
 167. Menasché P, Kevelaitis E, Mouas C, Grousset C, Piwnica A, Bloch G. Preconditioning with potassium channel openers. new concept for enhancing cardioplegic protection A? J Thorac Cardiovasc Surg 110: 1606–1613, 1995.
 168. Meneton P, Bloch‐Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, Ceiler D, Gehring D, Martins I, Salmon G, Boulanger CM, Nussberger J, Crozatier B, Gasc J‐M, Heudes D, Bruneval P, Doetschman T, Ménard J, Alhenc‐Gelas F. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein‐deficient mice. Proc Natl Acad Sci U S A 98: 2634–2639, 2001.
 169. Messadi‐Laribi E, Griol‐Charhbili V, Gaies E, Vincent MP, Heudes D, Meneton P, henc‐Gelas F, Richer C. Cardioprotection and kallikrein‐kinin system in acute myocardial ischaemia in mice. Clin Exp Pharmacol Physiol 35: 489–493, 2008.
 170. Milia AF, Gross V, Plehm R, De Silva JA Jr, Bader M, Luft FC. Normal blood pressure and renal function in mice lacking the bradykinin B2 receptor. Hypertension 37: 1473–1479, 2001.
 171. Milligan G, Kostenis E. Heterotrimeric G‐proteins: a short history. Br J Pharmacol 147 (Suppl 1): S46–S55, 2006.
 172. Mindroiu T, Scicli G, Perini F, Carretero OA, Scicli AG. Identification of a new kinin in human urine. J Biol Chem 261: 7407–7411, 1986.
 173. Mombouli J‐V, Illiano S, Nagao T, Scott‐Burden T, Vanhoutte PM. Potentiation of endothelium‐dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary artery involves both endothelium‐derived relaxing and hyperpolarizing factors. Circ Res 71: 137–144, 1992.
 174. Monteiro AC, Schmitz V, Morrot A, de Arruda LB, Nagajyothi F, Granato A, Pesquero JB, Muller‐Esterl W, Tanowitz HB, Scharfstein J. Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type‐1 responses. PLoS Pathog 3: 1730–1744, 2007.
 175. Monteiro AC, Scovino A, Raposo S, Gaze VM, Cruz C, Svensjo E, Narciso MS, Colombo AP, Pesquero JB, Feres‐Filho E, Nguyen KA, Sroka A, Potempa J, Scharfstein J. Kinin danger signals proteolytically released by gingipain induce Fimbriae‐specific IFN‐gamma‐ and IL‐17‐producing T cells in mice infected intramucosally with Porphyromonas gingivalis. J Immunol 183: 3700–3711, 2009.
 176. Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein‐kinin system: current and future pharmacological targets. J Pharmacol Sci 99: 6–38, 2005.
 177. Moreira CR, Schmaier AH, Mahdi F, da Motta G, Nader HB, Shariat‐Madar Z. Identification of prolylcarboxypeptidase as the cell matrix‐associated prekallikrein activator. FEBS Lett 523: 167–170, 2002.
 178. Muller DN, Dechend R, Mervaala EMA, Park J‐K, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC. NF‐κB inhibition ameliorates angiotensin II‐induced inflammatory damage in rats. Hypertension 35: 193–201, 2000.
 179. Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin‐converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 102: 829–832, 2000.
 180. Nakagawa M, Nasjletti A. Plasma kinin concentration in deoxycorticosterone‐salt hypertension. Hypertension 11: 411–415, 1988.
 181. Nakagawa M, Nasjletti A. Renal function as affected by inhibitors of kininase II and of neutral endopeptidase 24.11 in rats with and without desoxycorticosterone pretreatment. Adv Exp Med Biol 247: 495–499, 1989.
 182. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE, Heldin CH, ten Dijke P. Identification of Smad7, a TGFβ‐inducible antagonist of TGF‐β signalling. Nature 389: 631–635, 1997.
 183. Nasjletti A, Colina‐Chourio J, McGiff JC. Disappearance of bradykinin in the renal circulation of dogs. Effects of kininase inhibition. Circ Res 37: 59–65, 1975.
 184. Nasjletti A, McGiff JC, Colina‐Chourio J. Interrelations of the renal kallikrein‐kinin system and renal prostaglandins in the conscious rat. Influence of mineralocorticoids. Circ Res 43: 799–807, 1978.
 185. Ngo ML, Mahdi F, Kolte D, Shariat‐Madar Z. Upregulation of prolylcarboxypeptidase (PRCP) in lipopolysaccharide (LPS) treated endothelium promotes inflammation. J Inflamm (Lond) 6: 3, 2009.
 186. Noda K, Sasaguri M, Ideishi M, Ikeda M, Arakawa K. Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc Res 27: 334–340, 1993.
 187. Noda Y, Yamada K, Igic R, Erdös EG. Regulation of rat urinary and renal kallikrein and prekallikrein by corticosteroids. Proc Natl Acad Sci U S A 80: 3059–3063, 1983.
 188. Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. A local kallikrein‐kinin system is present in rat hearts. Hypertension 23: 919–923, 1994.
 189. Nolly H, Saed G, Carretero OA, Scicli G, Scicli AG. Adrenal kallikrein. Hypertension 21: 911–915, 1993.
 190. Nolly H, Scicli AG, Scicli G, Carretero OA. Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. Circ Res 56: 816–821, 1985.
 191. Odya CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdös EG. Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. J Biol Chem 253: 5927–5931, 1978.
 192. Ohkubo I, Kurachi K, Takasawa T, Shiokawa H, Sasaki M. Isolation of a human cDNA for α2‐thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry 23: 5691–5697, 1984.
 193. Okamoto H, Greenbaum LM. Kininogen substrates for trypsin and cathepsin D in human, rabbit and rat plasmas. Life Sci 32: 2007–2013, 1983.
 194. Okamoto H, Greenbaum LM. Pharmacological properties of T‐kinin (isoleucyl‐seryl‐bradykinin) from rat plasma. Biochem Pharmacol 32: 2637–2638, 1983.
 195. Omata K, Carretero OA, Itoh S, Scicli AG. Active and inactive kallikrein in rabbit connecting tubules and urine during low and normal sodium intake. Kidney Int 24: 714–718, 1983.
 196. Omata K, Carretero OA, Scicli AG, Jackson BA. Localization of active and inactive kallikrein (kininogenase activity) in the microdissected rabbit nephron. Kidney Int 22: 602–607, 1982.
 197. Omoro SA, Majid DSA, El‐Dahr SS, Navar LG. Kinin influences on renal regional blood flow responses to angiotensin‐converting enzyme inhibition in dogs. Am J Physiol 276: F271–F277, 1999.
 198. Osterrieder W, Müller RKM, Powell JS, Clozel J‐P, Hefti F, Baumgartner HR. Role of angiotensin II in injury‐induced neointima formation in rats. Hypertension 18 (Suppl II): II–60‐II‐64, 1991.
 199. Overlack A, Stumpe KO, Heck I, Ressel C, Kühnert M, Krück F. Identification of angiotensin II‐ and kinin‐dependent mechanisms in essential hypertension. In: Philipp T, Distler A, editors. Hypertension: Mechanisms and Management. Berlin: Springer‐Verlag, 1980, p. 183–191.
 200. Oza NB, Schwartz JH, Goud HD, Levinsky NG. Rat aortic smooth muscle cells in culture express kallikrein, kininogen, and bradykininase activity. J Clin Invest 85: 597–600, 1990.
 201. Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in atherosclerosis. Semin Immunopathol 31: 5–22, 2009.
 202. Pan H‐L, Chen S‐R, Scicli GM, Carretero OA. Cardiac interstitial bradykinin release during ischemia is enhanced by ischemic preconditioning. Am J Physiol Heart Circ Physiol 279: H116–H121, 2000.
 203. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning—a brief review of the evidence. Can J Physiol Pharmacol 73: 837–842, 1995.
 204. Pasquié JL, Herizi A, Jover B, Mimran A. Chronic bradykinin infusion and receptor blockade in angiotensin II hypertension in rats. Hypertension 33: 830–834, 1999.
 205. Pees C, Unger T, Gohlke P. Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats. Int J Biochem Cell Biol 35: 963–972, 2003.
 206. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327: 669–677, 1992.
 207. Picard N, Eladari D, El MS, Planes C, Bourgeois S, Houillier P, Wang Q, Burnier M, Deschenes G, Knepper MA, Meneton P, Chambrey R. Defective ENaC processing and function in tissue kallikrein‐deficient mice. J Biol Chem 283: 4602–4611, 2008.
 208. Picard N, Van AM, Campone C, Seiler M, Bloch‐Faure M, Hoenderop JG, Loffing J, Meneton P, Bindels RJ, Paillard M, henc‐Gelas F, Houillier P. Tissue kallikrein‐deficient mice display a defect in renal tubular calcium absorption. J Am Soc Nephrol 16: 3602–3610, 2005.
 209. Pietrovski EF, Otuki MF, Regoli D, Bader M, Pesquero JB, Cabrini DA, Zampronio AR. The non‐peptide kinin receptor antagonists FR 173657 and SSR 240612: Preclinical evidence for the treatment of skin inflammation. Regul Pept 152: 67–72, 2009.
 210. Pisano JJ, Corthorn J, Yates K, Pierce JV. The kallikrein‐kinin system in the kidney. Contrib Nephrol 12: 116–125, 1978.
 211. Pixley RA, Colman RW. The kallikrein‐kinin system in sepsis syndrome. In: Farmer SG, editor. The Kinin System. San Diego, CA: Academic Press Inc, 1997, p. 173–186.
 212. Pollock DM, Butterfield MI, Ader JL, Arendshorst WJ. Dissociation of urinary kallikrein activity and salt and water excretion in the rat. Am J Physiol 250: F1082–F1089, 1986.
 213. Pons S, Griol‐Charhbili V, Heymes C, Fornes P, Heudes D, Hagege A, Loyer X, Meneton P, Giudicelli JF, Samuel JL, henc‐Gelas F, Richer C. Tissue kallikrein deficiency aggravates cardiac remodelling and decreases survival after myocardial infarction in mice. Eur J Heart Fail 10: 343–351, 2008.
 214. Pontieri V, Lopes OU, Ferreira SH. Hypotensive effect of captopril. Role of bradykinin and prostaglandinlike substances. Hypertension 15 (Suppl I): I–55‐I‐58, 1990.
 215. Powell JS, Müller RKM, Rouge M, Kuhn H, Hefti F, Baumgartner HR. The proliferative response to vascular injury is suppressed by angiotensin‐converting enzyme inhibition. J Cardiovasc Pharmacol 16 (Suppl 4): S42–S49, 1990.
 216. Powers CA, Nasjletti A. A major sex difference in kallikrein‐like activity in the rat anterior pituitary. Endocrinology 114: 1841–1844, 1984.
 217. Prat A, Weinrib L, Becher B, Poirier J, Duquette P, Couture R, Antel JP. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 53: 2087–2092, 1999.
 218. Pravenec M, Kren V, Kunes J, Scicli AG, Carretero OA, Simonet L, Kurtz TW. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 17: 242–246, 1991.
 219. Rabito SF, Scicli AG, Carretero OA. Immunoreactive glandular kallikrein in plasma. In: Gross F, Vogel G, editors. Enzymatic Release of Vasoactive Peptides. New York: Raven Press, 1980, p. 247–256.
 220. Rabito SF, Scicli AG, Kher V, Carretero OA. Immunoreactive glandular kallikrein in rat plasma: A radioimmunoassay for its determination. Am J Physiol 242: H602–H610, 1982.
 221. Regoli D. Pharmacology of bradykinin and related kinins. Adv Exp Med Biol 156: 569–584, 1983.
 222. Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1–46, 1980.
 223. Regoli D, Rhaleb N‐E, Dion S, Drapeau G. New selective bradykinin receptor antagonists and bradykinin B2 receptor characterization. Trends Pharmacol Sci 11: 156–161, 1990.
 224. Regoli D, Rhaleb N‐E, Drapeau G, Dion S. Kinin receptor subtypes. J Cardiovasc Pharmacol 15 (Suppl 6): S30–S38, 1990.
 225. Regoli D, Rhaleb N‐E, Drapeau G, Dion S, Tousignant C, D'Orl:eans‐Juste P, Devillier P. Basic pharmacology of kinins: pharmacologic receptors and other mechanisms. Adv Exp Med Biol 247: 399–407, 1989.
 226. Ren Y, Garvin J, Carretero OA. Mechanism involved in bradykinin‐induced efferent arteriole dilation. Kidney Int 62: 544–549, 2002.
 227. Rett K, Wicklmayr M, Dietze GJ, Häring HU. Insulin‐induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 45 (Suppl. 1): S66–S69, 1996.
 228. Rhaleb N‐E, Peng H, Alfie M, Shesely EG, Carretero OA. Effect of ACE inhibitor on DOCA‐salt‐ and aortic coarctation‐induced hypertension in mice. Do kinin B2 receptors play a role? Hypertension 33: 329–334, 1999.
 229. Rhaleb N‐E, Yang X‐P, Nanba M, Shesely EG, Carretero OA. Effect of chronic blockade of the kallikrein‐kinin system on the development of hypertension in rats. Hypertension 37: 121–128, 2001.
 230. Rhaleb N‐E, Yang X‐P, Peng H, Cavasin MA, Liu YH, Yang F, Xu J, Carretero OA. Cardiovascular phenotype of male 129/SvEvTac, 129/SvJ and B2‐KO mice [abstract]. FASEB J 15: A101, 2001.
 231. Rhaleb N‐E, Yang X‐P, Scicli AG, Carretero OA. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril. Hypertension 23: 865–868, 1994.
 232. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ. Rosuvastatin to prevent vascular events in men and women with elevated C‐reactive protein. N Engl J Med 359: 2195–2207, 2008.
 233. Rodriguez‐Iturbe B, Quiroz Y, Nava M, Bonet L, Chavez M, Herrera‐Acosta J, Johnson RJ, Pons HA. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282: F191–F201, 2002.
 234. Roman RJ, Kaldunski ML, Scicli AG, Carretero OA. Influence of kinins and angiotensin II on the regulation of papillary blood flow. Am J Physiol 255: F690–F698, 1988.
 235. Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis. Coronary‐vasodilating and antiarrhythmic activities mediated by autocrine/paracrine mechanisms. Circ Res 76: 434–440, 1995.
 236. Sabatini RA, Guimaraes PB, Fernandes L, Reis FC, Bersanetti PA, Mori MA, Navarro A, Hilzendeger AM, Santos EL, Andrade MC, Chagas JR, Pesquero JL, Casarini DE, Bader M, Carmona AK, Pesquero JB. ACE activity is modulated by kinin B2 receptor. Hypertension 51: 689–695, 2008.
 237. Saed GM, Carretero OA, MacDonald RJ, Scicli AG. Kallikrein messenger RNA in rat arteries and veins. Circ Res 67: 510–516, 1990.
 238. Saha JK, Sengupta JN, Goyal RK. Effect of bradykinin on opossum esophageal longitudinal smooth muscle: Evidence for novel bradykinin receptors. J Pharmacol Exp Ther 252: 1012–1020, 1990.
 239. Saitoh S, Scicli AG, Peterson E, Carretero OA. Effect of inhibiting renal kallikrein on prostaglandin E2, water, and sodium excretion. Hypertension 25: 1008–1013, 1995.
 240. Salgado MCO, Rabito SF, Carretero OA. Blood kinin in one‐kidney, one clip hypertensive rats. Hypertension 8 (Suppl I): I–110‐I‐113, 1986.
 241. Sasaki N, Yamashita T, Takeda M, Shinohara M, Nakajima K, Tawa H, Usui T, Hirata K. Oral anti‐CD3 antibody treatment induces regulatory T cells and inhibits the development of atherosclerosis in mice. Circulation 120: 1996–2005, 2009.
 242. Schachter M, Longridge DJ, Wheeler GD, Mehta JG, Uchida Y. Immunocytochemical and enzyme histochemical localization of kallikrein‐like enzymes in colon, intestine, and stomach of rat and cat. J Histochem Cytochem 34: 927–934, 1986.
 243. Scharfstein J, Monteiro AC, Schmitz V, Svensjo E. Angiotensin‐converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: A peripheral mechanism regulating adaptive immunity via the innate kinin pathway. Biol Chem 389: 1015–1024, 2008.
 244. Scharfstein J, Schmitz V, Svensjo E, Granato A, Monteiro AC. Kininogens coordinate adaptive immunity through the proteolytic release of bradykinin, an endogenous danger signal driving dendritic cell maturation. Scand J Immunol 66: 128–136, 2007.
 245. Schmaier AH. Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int Immunopharmacol 8: 161–165, 2008.
 246. Schmitz V, Svensjo E, Serra RR, Teixeira MM, Scharfstein J. Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll‐like 2 receptors. J Leukoc Biol 85: 1005–1014, 2009.
 247. Schoelkens BA, Linz W. Bradykinin‐mediated metabolic effects in isolated perfused rat hearts. Agents Actions Suppl 38: 36–42, 1992.
 248. Schölkens BA, Linz W, Martorana PA. Experimental cardiovascular benefits of angiotensin‐converting enzyme inhibitors: beyond blood pressure reduction. J Cardiovasc Pharmacol 18 (Suppl. 2): S26–S30, 1991.
 249. Schulze‐Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, Bendix I, Ifergan I, Schadock I, Mori MA, Van HJ, Schroter F, Smorodchenko A, Han MH, Bader M, Steinman L, Aktas O, Zipp F. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15: 788–793, 2009.
 250. Scicli AG, Carbini LA, Carretero OA. The molecular biology of the kallikrein‐kinin system: II. The rat gene family. J Hypertens 11: 775–780, 1993.
 251. Scicli AG, Carretero OA, Hampton A, Cortes P, Oza NB. Site of kininogenase secretion in the dog nephron. Am J Physiol 230: 533–536, 1976.
 252. Scicli AG, Gandolfi R, Carretero OA. Site of formation of kinins in the dog nephron. Am J Physiol 234: F36–F40, 1978.
 253. Scicli AG, Mindroiu T, Scicli G, Carretero OA. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J Lab Clin Med 100: 81–93, 1982.
 254. Scicli AG, Ørstavik TB, Rabito SF, Murray RD, Carretero OA. Blood kinins after sympathetic nerve stimulation of the rat submandibular gland. Hypertension 5 (Suppl I): I–101‐I‐106, 1983.
 255. Scicli G, Nolly H, Carretero OA, Scicli AG. Glandular kallikrein‐like enzyme in adrenal glands. Adv Exp Med Biol 247B: 217–222, 1989.
 256. Seino M, Abe K, Nushiro N, Omata K, Kasai Y, Yoshinaga K. Effects of a competitive antagonist of bradykinin on blood pressure and renal blood flow in anesthetized rats. J Hypertens 6: 867–871, 1988.
 257. Seino M, Abe K, Otsuka Y, Saito T, Irokawa N, Yasujima M, Ciba S, Yoshinaga K. Urinary kallikrein excretion and sodium metabolism in hypertensive patients. Tohoku J Exp Med 116: 359–367, 1975.
 258. Seino M, Carretero OA, Albertini R, Scicli AG. Kinins in regulation of uteroplacental blood flow in the pregnant rabbit. Am J Physiol 242: H142–H147, 1982.
 259. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C‐reactive protein and the risk of developing hypertension. JAMA 290: 2945–2951, 2003.
 260. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 26: 164–170, 1995.
 261. Shariat‐Madar Z, Mahdi F, Schmaier AH. Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator. J Biol Chem 277: 17962–17969, 2002.
 262. Shariat‐Madar Z, Mahdi F, Schmaier AH. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood 103: 4554–4561, 2004.
 263. Sharma JN, Wirth KJ. Inhibition of rats adjuvant arthritis by a bradykinin antagonist Hoe 140 and its influence on kallikreins. Gen Pharmacol 27: 133–136, 1996.
 264. Sinaiko AR, Glasser RJ, Gillum RF, Prineas RJ. Urinary kallikrein excretion in grade school children with high and low blood pressure. J Pediatr 100: 938–940, 1982.
 265. Siragy HM, Inagami T, Ichiki T, Carey RM. Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype‐2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 96: 6506–6510, 1999.
 266. Siragy HM, Jaffa AA, Margolius HS. Stimulation of renal interstitial bradykinin by sodium depletion. Am J Hypertens 6: 863–866, 1993.
 267. Skidgel RA, Schulz WW, Tam L‐T, Erdös EG. Human renal angiotensin I converting enzyme and neutral endopeptidase. Kidney Int 31 (Suppl 20): S–45‐S‐48, 1987.
 268. Smith D, Gilbert M, Owen WG. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66: 835–839, 1985.
 269. Speechly‐Dick ME, Mocanu MM, Yellon DM. Protein kinase C. Its role in ischemic preconditioning in the rat. Circ Res 75: 586–590, 1994.
 270. Stewart JM. Bradykinin antagonists as anti‐cancer agents. Curr Pharm Des 9: 2036–2042, 2003.
 271. Stewart JM, Gera L, York EJ, Chan DC, Whalley EJ, Bunn PA Jr, Vavrek RJ. Metabolism‐resistant bradykinin antagonists: development and applications. Biol Chem 382: 37–41, 2001.
 272. Stewart JM, Vavrek RJ. Bradykinin competitive antagonists for classical kinin systems. Adv Exp Med Biol 198: 537–542, 1986.
 273. Stoos BA, Carretero OA, Farhy RD, Scicli G, Garvin JL. Endothelium‐derived relaxing factor inhibits transport and increases cGMP content in cultured mouse cortical collecting duct cells. J Clin Invest 89: 761–765, 1992.
 274. Sueyoshi T, Enjyoji K, Shimada T, Kato H, Iwanaga S, Bando Y, Kominami E, Katunuma N. A new function of kininogens as thiol‐proteinase inhibitors: inhibition of papain and cathepsins B, H and L by bovine, rat and human plasma kininogens. FEBS Lett 182: 193–195, 1985.
 275. Sugawara A, Kudo M, Saito A, Matsuda K, Uruno A, Ito S. Novel effects of beraprost sodium on vasculatures. Int Angiol 29: 28–32, 2010.
 276. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone‐induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 161: 1773–1781, 2002.
 277. Sundsmo JS, Fair DS. Relationships among the complement, kinin, coagulation and fibrinolytic systems in the inflammatory reaction. Clin Physiol Biochem 1: 225–284, 1983.
 278. Sustarsic DL, McPartland RP, Rapp JP, Schlager G, Tan SY. Urinary kallikrein and urinary prostaglandin E2 in genetically hypertensive mice. Proc Soc Exp Biol Med 163: 193–199, 1980.
 279. Sybertz EJ, Chiu PJS, Vemulapalli S, Watkins R, Haslanger MF. Atrial natriuretic factor‐potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor. Hypertension 15: 152–161, 1990.
 280. Tiffany CW, Burch RM. Bradykinin stimulates tumor necrosis factor and interleukin‐1 release from macrophages. FEBS Lett 247: 189–192, 1989.
 281. Tomita K, Pisano JJ. Binding of [3H]bradykinin in isolated nephron segments of the rabbit. Am J Physiol 246: F732–F737, 1984.
 282. Tomiyama H, Scicli AG, Scicli GM, Carretero OA. Renal effects of Fab fragments of kinin antibodies on deoxycorticosterone acetate‐salt‐treated rats. Hypertension 15: 761–766, 1990.
 283. Tornel J, Madrid MI, García‐Salom M, Wirth KJ, Fenoy FJ. Role of kinins in the control of renal papillary blood flow, pressure natriuresis, and arterial pressure. Circ Res 86: 589–595, 2000.
 284. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14: 125–131, 2005.
 285. Trabold F, Pons S, Hagege AA, Bloch‐Faure M, Alhenc‐Gelas F, Giudicelli J‐F, Richer‐Giudicelli C, Meneton P. Cardiovascular phenotypes of kinin B2 receptor‐ and tissue kallikrein‐deficient mice. Hypertension 40: 90–95, 2002.
 286. Trabold R, Eros C, Zweckberger K, Relton J, Beck H, Nussberger J, Muller‐Esterl W, Bader M, Whalley E, Plesnila N. The role of bradykinin B(1) and B(2) receptors for secondary brain damage after traumatic brain injury in mice. J Cereb Blood Flow Metab 30: 130–139, 2010.
 287. Tschöpe C, Gohlke P, Zhu Y‐Z, Linz W, Schölkens B, Unger T. Antihypertensive and cardioprotective effects after angiotensin‐ converting enzyme inhibition: Role of kinins. J Card Fail 3: 133–148, 1997.
 288. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104: 925–935, 1999.
 289. Uchiyama M, Otsuka T, Sakai K. Urinary kallikrein excretion in children of parents with essential hypertension. Arch Dis Child 60: 974–975, 1985.
 290. Ura N, Carretero OA, Erdös EG. Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo. Kidney Int 32: 507–513, 1987.
 291. Vane JR, Änggård EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 323: 27–36, 1990.
 292. Vanhoutte PM. Endothelium and control of vascular function. State of the art lecture. Hypertension 13: 658–667, 1989.
 293. Vegh A, Szekeres L, Parratt JR. Protective effects of preconditioning of the ischaemic myocardium involve cyclo‐oxygenase products. Cardiovasc Res 24: 1020–1023, 1990.
 294. Vijayaraghavan J, Scicli AG, Carretero OA, Slaughter C, Moomaw C, Hersh LB. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 265: 14150–14155, 1990.
 295. Vinci JM, Horwitz D, Zusman RM, Pisano JJ, Catt KJ, Keiser HR. The effect of converting enzyme inhibition with SQ20,881 on plasma and urinary kinins, prostaglandin E and angiotensin II in hypertensive man. Hypertension 1: 416–426, 1979.
 296. Vio CP, Churchill L, Rabito SF, Terragno A, Carretero OA, Terragno NA. Renal kallikrein in venous effluent of filtering and non‐filtering isolated kidneys. Adv Exp Med Biol 156B: 897–905, 1983.
 297. Virdis A, Schiffrin EL. Vascular inflammation: A role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 12: 181–187, 2003.
 298. Wang H, Carretero OA, Garvin JL. Inhibition of apical Na+/H+ exchangers on the macula densa cells augments tubuloglomerular feedback. Hypertension 41: 688–691, 2003.
 299. Wei M, Wang X, Kuukasjarvi P, Laurikka J, Rinne T, Honkonen EL, Tarkka M. Bradykinin preconditioning in coronary artery bypass grafting. Ann Thorac Surg 78: 492–497, 2004.
 300. Whalley ET, Hanson WL, Stewart JM, Gera L. Oral activity of peptide bradykinin antagonists following intragastric administration in the rat. Can J Physiol Pharmacol 75: 629–632, 1997.
 301. Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, König W, Knolle J, Schölkens BA. Hoe 140 a new potent and long acting bradykinin‐antagonist: In vivo studies. Br J Pharmacol 102: 774–777, 1991.
 302. Witherow FN, Helmy A, Webb DJ, Fox KAA, Newby DE. Bradykinin contributes to the vasodilator effects of chronic angiotensin‐converting enzyme inhibition in patients with heart failure. Circulation 104: 2177–2181, 2001.
 303. Wolfrum S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote preconditioning protects the heart by activating myocardial PKCɛ‐isoform. Cardiovasc Res 55: 583–589, 2002.
 304. Wollheim E, Peterknecht S, Dees C, Wiener A, Wollheim CB. Defect in the excretion of a vasoactive polypeptide fraction A possible genetic marker of primary hypertension. Hypertension 3: 574–579, 1981.
 305. Wu H, Ghosh S, Perrard XD, Feng L, Garcia GE, Perrard JL, Sweeney JF, Peterson LE, Chan L, Smith CW, Ballantyne CM. T‐cell accumulation and regulated on activation, normal T cell expressed and secreted upregulation in adipose tissue in obesity. Circulation 115: 1029–1038, 2007.
 306. Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang X‐P. Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension 40: 244–250, 2002.
 307. Xu J, Carretero OA, Liu YH, Yang F, Shesely EG, Oja‐Tebbe N, Yang X‐P. Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure. J Card Fail 10: 83–89, 2004.
 308. Xu J, Carretero OA, Shesely EG, Rhaleb N‐E, Yang JJ, Bader M, Yang X‐P. The kinin B1 receptor contributes to the cardioprotective effect of angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in mice. Exp Physiol 94: 322–329, 2009.
 309. Yamaguchi T, Carretero OA, Scicli AG. A novel serine protease with vasoconstrictor activity coded by the kallikrein gene S3. J Biol Chem 266: 5011–5017, 1991.
 310. Yamaguchi T, Carretero OA, Scicli AG. A potent vasoconstrictor in the rat submandibular gland. Hypertension 17: 101–106, 1991.
 311. Yang X‐P, Liu YH, Mehta D, Cavasin MA, Shesely EG, Xu J, Liu F, Carretero OA. Diminished cardioprotective response to inhibition of angiotensin‐converting enzyme and angiotensin II type 1 receptor in B2 kinin receptor gene knockout mice. Circ Res 88: 1072–1079, 2001.
 312. Yang X‐P, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning. Study of myocardial ischemia/reperfusion injury in B2 kinin receptor knockout mice and kininogen‐deficient rats. Hypertension 30: 735–740, 1997.
 313. Yang X‐P, Liu YH, Shesely EG, Bulagannawar M, Liu F, Carretero OA. Endothelial nitric oxide gene knockout mice. Cardiac phenotypes and the effect of angiotensin‐converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension 34: 24–30, 1999.
 314. Yin H, Chao L, Chao J. Kallikrein/kinin protects against myocardial apoptosis after ischemia/reperfusion via Akt‐glycogen synthase kinase‐3 and Akt‐Bad.14‐3‐3 signaling pathways. J Biol Chem 280: 8022–8030, 2005.
 315. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 266: H1145–H1152, 1994.
 316. Zhang H, Wang H, Bassel‐Duby R, Maass DL, Johnston WE, Horton JW, Tao W. Role of interleukin‐6 in cardiac inflammation and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Physiol 292: H2408–H2416, 2007.
 317. Zhou X, Ferraris JD, Cai Q, Agarwal A, Burg MB. Increased reactive oxygen species contribute to high NaCl‐induced activation of the osmoregulatory transcription factor TonEBP/OREBP. Am J Physiol Renal Physiol 289: F377–F385, 2005.
 318. Zhu L, Carretero OA, Liao T, Harding P, Li H, Sumners C, Yang X‐P. Role of prolylcarboxypeptidase in angiotensin II type 2 receptor‐mediated bradykinin release in mouse coronary artery endothelial cells. Hypertension 56: 384–390, 2010.
 319. Zimmerman BG, Raich PC, Vavrek RJ, Stewart JM. Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in the conscious sodium‐restricted dog. Circ Res 66: 234–240, 1990.
 320. Zimmermann A, Geiger R, Kortmann H. Similarity between a kininogenase (kallikrein) from human large intestine and human urinary kallikrein. Hoppe Seylers Z Physiol Chem 360: 1767–1773, 1979.
 321. Zinner SH, Margolius HS, Rosner B, Keiser HR, Kass EH. Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol 104: 124–132, 1976.
 322. Zuccollo A, Navarro M, Frontera M, Cueva F, Carattino M, Catanzaro OL. The involvement of kallikrein‐kinin system in diabetes type I (insulitis). Immunopharmacology 45: 69–74, 1999.
 323. Zweckberger K, Plesnila N. Anatibant, a selective non‐peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury. Neurosci Lett 454: 115–117, 2009.
 324. Ørstavik TB, Carretero OA, Johansen L, Scicli AG. Role of kallikrein in the hypotensive effect of captopril after sympathetic stimulation of the rat submandibular gland. Circ Res 51: 385–390, 1982.

Related Articles:

Molecular and Physiological Aspects of Angiotensin I Converting Enzyme
Renal Circulation
Immunity and Inflammation
Systemic Hypertension

Contact Editor

Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: The Kallikrein‐Kinin System as a Regulator of Cardiovascular and Renal Function
 

How to Cite

Nour‐Eddine Rhaleb, Xiao‐Ping Yang, Oscar A. Carretero. The Kallikrein‐Kinin System as a Regulator of Cardiovascular and Renal Function. Compr Physiol 2011, 1: 971-993. doi: 10.1002/cphy.c100053